Atopic Dermatitis Treatment

CE / CME

Targeting IL-13: A New Era in Atopic Dermatitis Treatment 

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Nurses: 0.25 Nursing contact hour

Physicians: maximum of 0.25 AMA PRA Category 1 Credit

ABIM MOC: maximum of 0.25 Medical Knowledge MOC point

Released: December 13, 2024

Expiration: December 12, 2025

Daniel C. Butler
Daniel C. Butler, MD

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

A 34-year-old patient with moderate to severe AD presents with chronic pruritus, widespread eczematous lesions, and persistent symptoms despite topical corticosteroids and emollients. The patient has no history of asthma or other allergic conditions. You are considering systemic biologic therapy targeting IL-13 to address the underlying pathophysiology of the patient’s AD.

Based on current evidence, which therapy would be the most appropriate option for this patient?